Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,426

Decoy antibiotics could get around bacteria’s defences

Imperial medical students have helped to devise a new type of ‘decoy’ drug to tackle infections that are resistant to antibiotics.

In lab tests on bacterial cultures, the new successfully killed a strain of . It works by delivering two antibiotics, one of which is effectively hidden. When the fight against the first ‘decoy’ antibiotic, this action opens up the drug, triggering the second antibiotic into action.

This enables the second antibiotic to be delivered in a targeted way, only being released where it encounters drug-resistant bacteria. The findings could help prolong the life of existing antibiotics by slowing the rate at which bacteria become resistant to them.

Read more

A new way to wind the development clock of cardiac muscle cells

These days, scientists can collect a few skin or blood cells, wipe out their identities, and reprogram them to become virtually any other kind of cell in the human body, from neurons to heart cells.

The journey from skin cell to another type of functional cell involves converting them into induced (iPSCs), which are similar to the developmentally immature stem cells found in embryos, and then coaxing them to mature into something different.

But the process runs on an invisible clock, one in which scientists are interested in speeding up so adult-like cells are available when needed, whether for testing drugs for precision medicine, transplanting to repair injury or defect, or better understanding basic biology. It involves an FDA-approved compound called polyinosine-polycytidylic acid, or pIC, a double-stranded RNA molecule that activates a cell’s innate defense system. The compound is commonly used to boost vaccines and chemotherapy. The researchers found that when added to induced pluripotent stem cells undergoing the process of transitioning into cardiac muscle cells, pIC accelerated cellular .

Read more

A hydrogel that can stop bleeding from an artery

A team of researchers affiliated with several institutions in China has developed a hydrogel that can stop bleeding from a punctured artery. In their paper published in the journal Nature Communications, the group describes how the hydrogel was made and how well it worked on test animals.

Uncontrolled bleeding is a very serious situation, both during surgical procedures and as a result of trauma. In most cases, it is the result of damage to a major artery or an organ like the liver. In all cases, immediate action must be taken or the victim will die. Currently, treatment for such involves clamping the artery and then using sutures to close the wound. In the past, researchers have attempted to create a type of glue to stem such wounds, but thus far, none of them has worked as hoped—they were either made of or were not strong enough to stand up to the high liquid pressure in the bloodstream. In this new effort, the researchers have developed a new type of that solves both problems.

The researchers report that the hydrogel is made of water, gelatin and a mix of proteins and other chemicals. It was designed to be as close as possible in structure to human connective tissues. When UV light shines on the gel, it thickens and solidifies, adhering to the wound, preventing blood from flowing out. And it does so in just 20 to 30 seconds. The researchers note that it could also stand up to 290-mmHg blood pressure—much higher than normal.

Read more

Goodbye Surgery – Scientists Made Eye Drops That Dissolve Cataracts

American researchers have recently published a study in the scientific journal Nature, showing promising results using steroid eye drops for shrinking down and dissolving cataracts.

At the moment cataracts is the leading cause of blindness, and can only be removed through surgery. The surgical procedure, while simple and safe, is unpleasant for the patient and often prohibitively expensive.

A ccording to the Fred Hollows Foundation, approximately 32.4 million people around the world are blind, with more than half of the cases being caused by cataracts. In the United States alone, nearly 22 million Americans who are over age 40 have cataracts, according to the American Academy of Ophthalmology.

Read more

Neanderthals and modern humans diverged at least 800,000 years ago

Substantially earlier than indicated by most DNA-based estimates, according to new research by a UCL academic.

The research, published in Science Advances, analysed dental evolutionary rates across different , focusing on early Neanderthals. It shows that the of hominins from Sima de los Huesos, Spain—ancestors of the Neanderthals—diverged from the modern lineage earlier than previously assumed.

Sima de los Huesos is a cave site in Atapuerca Mountains, Spain, where archaeologists have recovered fossils of almost 30 people. Previous studies date the site to around 430,000 years ago (Middle Pleistocene), making it one of the oldest and largest collections of human remains discovered to date.

Read more

Alternative Cancer Treatments Brought to Legitimacy at Scientific Forum in San Diego

The world recently acknowledged the power of alternative cancer treatments by awarding the 2018 Nobel Prize in Medicine to Dr. James P. Allison and Dr. Tasuku Honjo for their work in immunotherapy. More specifically on checkpoint inhibitor therapies.

Until recently many in the scientific community had dismissed immunotherapy as a viable cancer treatment. Nevertheless, Allison and Honjo persevered and their breakthrough has allowed for the classification of new drugs and treatments that may help patients have run out of options.

Ironically, while many in the mainstream are barely learning of immunotherapy, a hospital in Mexico, CHIPSA Hospital, has been working with these treatments for over 38 year and often under fire from public ridicule that their treatments are strange and ineffective.

Read more

The Future of Pensions

Nicola Bagalà and Michael Nuschke take a look at the future of pensions and how the possible defeat of age-related diseases will affect them.

If you work in social security, it’s possible that your nightmares are full of undying elderly people who keep knocking on your door for pensions that you have no way of paying out. Tossing and turning in your bed, you beg for mercy, explaining that there’s just too many old people who need pensions and not enough young people who could cover for it with their contributions; the money’s just not there to sustain a social security system that, when it was conceived in the mid-1930s, didn’t expect that many people would ever make it into their 80s and 90s. Your oneiric persecutors won’t listen: they gave the country the best years of their lives, and now it’s time for the country to pay them their due.

When you wake up, you’re relieved to realize that there can’t be any such thing as people who have ever-worsening degenerative diseases yet never die from them, but that doesn’t make your problem all that better; you still have quite a few old people, living longer than the pension system had anticipated, to pay pensions to, and the bad news is that in as little as about 30 years, the number of 65+ people worldwide will skyrocket to around 2.1 billion, growing faster than all younger groups put together [1]. Where in the world is your institution going to find the budget?

Read more

How whales defy the cancer odds: Good genes

But they don’t. Instead, they are less likely to develop or die of this enigmatic disease. The same is true of elephants and dinosaurs’ living relatives, birds. Marc Tollis, an assistant professor in the School of Informatics, Computing, and Cyber Systems at Northern Arizona University, wants to know why.

Tollis led a team of scientists from Arizona State University, the University of Groningen in the Netherlands, the Center for Coastal Studies in Massachusetts and nine other institutions worldwide to study potential cancer suppression mechanisms in cetaceans, the mammalian group that includes whales, dolphins and porpoises. Their findings, which picked apart the genome of the humpback whale, as well as the genomes of nine other cetaceans, in order to determine how their cancer defenses are so effective, were published today in Molecular Biology and Evolution.

The study is the first major contribution from the newly formed Arizona Cancer and Evolution Center or ACE, directed by Carlo Maley under an $8.5 million award from the National Cancer Institute. Maley, an evolutionary biologist, is a researcher at ASU’s Biodesign Virginia G. Piper Center for Personalized Diagnostics and professor in the School of Life Sciences. He is a senior co-author of the new study.